Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines

R. J. Chen, W. S. Lee, Y. C. Liang, J. K. Lin, Y. J. Wang, Chien-Huang Lin, J. Y. Hsieh, C. C. Chaing, Y. S. Ho

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Ketoconazole is an oral-antifungal agent that has been used worldwide in the treatment of some hormone-dependent human cancer. In this study, we demonstrated that ketoconazole (20 μM) induced various types of human cancer cell growth arrest in the G0/G1 phase. Our results revealed that ketoconazole-induced growth arrest was more profound in COLO 205 and Hep G2 (with wild-type p53) than in HT 29 (p53 His273 mutant) and Hep 3B (with deleted p53) cells. The protein levels of p53, p21/Cip1, and p27/Kip1 were significantly elevated by ketoconazole (10 μM) treatment in COLO 205 but not in HT 29 cells. The ketoconazole-induced G0/G1 phase arrest in COLO 205 cells was attenuated by p53-specific antisense oligodeoxynucleotides (20 μM) treatment. These results suggested that the p53-associated signaling pathway is involved in the regulation of ketoconazole-induced cancer cell growth arrest. By Western blot analysis, we demonstrated that cyclin D3 and CDK4 protein but not other G0/G1 phase regulatory protein levels were decreased by ketoconazole-treatment in both COLO 205 and HT 29 cells. Our study provides the basis of molecular mechanisms for ketoconazole in growth inhibition of human cancer cells and such results may have significant applications for cancer chemotherapy. (C) 2000 Academic Press.

Original languageEnglish
Pages (from-to)132-141
Number of pages10
JournalToxicology and Applied Pharmacology
Volume169
Issue number2
DOIs
Publication statusPublished - Dec 1 2000

Fingerprint

Ketoconazole
Hepatocellular Carcinoma
Colorectal Neoplasms
Cells
Cell Line
Cell Cycle Resting Phase
G1 Phase
HT29 Cells
Cell growth
Neoplasms
Growth
Cyclin D3
Proteins
Chemotherapy
Oligodeoxyribonucleotides
Antifungal Agents
Therapeutics
Western Blotting
Hormones
Drug Therapy

Keywords

  • Cip1
  • G0
  • G1 arrest
  • Ketoconazole
  • p21
  • p53

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines. / Chen, R. J.; Lee, W. S.; Liang, Y. C.; Lin, J. K.; Wang, Y. J.; Lin, Chien-Huang; Hsieh, J. Y.; Chaing, C. C.; Ho, Y. S.

In: Toxicology and Applied Pharmacology, Vol. 169, No. 2, 01.12.2000, p. 132-141.

Research output: Contribution to journalArticle

@article{b06e4d3c0bff40a6bd9b5152e6e37bc2,
title = "Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines",
abstract = "Ketoconazole is an oral-antifungal agent that has been used worldwide in the treatment of some hormone-dependent human cancer. In this study, we demonstrated that ketoconazole (20 μM) induced various types of human cancer cell growth arrest in the G0/G1 phase. Our results revealed that ketoconazole-induced growth arrest was more profound in COLO 205 and Hep G2 (with wild-type p53) than in HT 29 (p53 His273 mutant) and Hep 3B (with deleted p53) cells. The protein levels of p53, p21/Cip1, and p27/Kip1 were significantly elevated by ketoconazole (10 μM) treatment in COLO 205 but not in HT 29 cells. The ketoconazole-induced G0/G1 phase arrest in COLO 205 cells was attenuated by p53-specific antisense oligodeoxynucleotides (20 μM) treatment. These results suggested that the p53-associated signaling pathway is involved in the regulation of ketoconazole-induced cancer cell growth arrest. By Western blot analysis, we demonstrated that cyclin D3 and CDK4 protein but not other G0/G1 phase regulatory protein levels were decreased by ketoconazole-treatment in both COLO 205 and HT 29 cells. Our study provides the basis of molecular mechanisms for ketoconazole in growth inhibition of human cancer cells and such results may have significant applications for cancer chemotherapy. (C) 2000 Academic Press.",
keywords = "Cip1, G0, G1 arrest, Ketoconazole, p21, p53",
author = "Chen, {R. J.} and Lee, {W. S.} and Liang, {Y. C.} and Lin, {J. K.} and Wang, {Y. J.} and Chien-Huang Lin and Hsieh, {J. Y.} and Chaing, {C. C.} and Ho, {Y. S.}",
year = "2000",
month = "12",
day = "1",
doi = "10.1006/taap.2000.9062",
language = "English",
volume = "169",
pages = "132--141",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines

AU - Chen, R. J.

AU - Lee, W. S.

AU - Liang, Y. C.

AU - Lin, J. K.

AU - Wang, Y. J.

AU - Lin, Chien-Huang

AU - Hsieh, J. Y.

AU - Chaing, C. C.

AU - Ho, Y. S.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Ketoconazole is an oral-antifungal agent that has been used worldwide in the treatment of some hormone-dependent human cancer. In this study, we demonstrated that ketoconazole (20 μM) induced various types of human cancer cell growth arrest in the G0/G1 phase. Our results revealed that ketoconazole-induced growth arrest was more profound in COLO 205 and Hep G2 (with wild-type p53) than in HT 29 (p53 His273 mutant) and Hep 3B (with deleted p53) cells. The protein levels of p53, p21/Cip1, and p27/Kip1 were significantly elevated by ketoconazole (10 μM) treatment in COLO 205 but not in HT 29 cells. The ketoconazole-induced G0/G1 phase arrest in COLO 205 cells was attenuated by p53-specific antisense oligodeoxynucleotides (20 μM) treatment. These results suggested that the p53-associated signaling pathway is involved in the regulation of ketoconazole-induced cancer cell growth arrest. By Western blot analysis, we demonstrated that cyclin D3 and CDK4 protein but not other G0/G1 phase regulatory protein levels were decreased by ketoconazole-treatment in both COLO 205 and HT 29 cells. Our study provides the basis of molecular mechanisms for ketoconazole in growth inhibition of human cancer cells and such results may have significant applications for cancer chemotherapy. (C) 2000 Academic Press.

AB - Ketoconazole is an oral-antifungal agent that has been used worldwide in the treatment of some hormone-dependent human cancer. In this study, we demonstrated that ketoconazole (20 μM) induced various types of human cancer cell growth arrest in the G0/G1 phase. Our results revealed that ketoconazole-induced growth arrest was more profound in COLO 205 and Hep G2 (with wild-type p53) than in HT 29 (p53 His273 mutant) and Hep 3B (with deleted p53) cells. The protein levels of p53, p21/Cip1, and p27/Kip1 were significantly elevated by ketoconazole (10 μM) treatment in COLO 205 but not in HT 29 cells. The ketoconazole-induced G0/G1 phase arrest in COLO 205 cells was attenuated by p53-specific antisense oligodeoxynucleotides (20 μM) treatment. These results suggested that the p53-associated signaling pathway is involved in the regulation of ketoconazole-induced cancer cell growth arrest. By Western blot analysis, we demonstrated that cyclin D3 and CDK4 protein but not other G0/G1 phase regulatory protein levels were decreased by ketoconazole-treatment in both COLO 205 and HT 29 cells. Our study provides the basis of molecular mechanisms for ketoconazole in growth inhibition of human cancer cells and such results may have significant applications for cancer chemotherapy. (C) 2000 Academic Press.

KW - Cip1

KW - G0

KW - G1 arrest

KW - Ketoconazole

KW - p21

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0034386967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034386967&partnerID=8YFLogxK

U2 - 10.1006/taap.2000.9062

DO - 10.1006/taap.2000.9062

M3 - Article

C2 - 11097865

AN - SCOPUS:0034386967

VL - 169

SP - 132

EP - 141

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 2

ER -